Pharmanovia signs in-licensing deal for novel osteoporosis treatment with Radius Health

• PHARMANOVIA PARTNERS WITH RADIUS HEALTH TO REGISTER AND COMMERCIALISE ABALOPARATIDE FOR THE TREATMENT OF OSTEOPOROSIS IN CHINA AND SEVERAL IMPORTANT HIGH GROWTH ASIA PACIFIC TERRITORIES
• THE DEAL EXPANDS PHARMANOVIA’S OSTEOPOROSIS FRANCHISE ADDING A NOVEL BONE FORMATION AGENT

BASILDON, UK, 02 January 2025

Pharmanovia, a global pharmaceutical company that commercialises novel medicines and revitalises, extends and expands the lifecycle of established medicines, today announced an exclusive in-licensing agreement with Radius Health, Inc for osteoporosis treatment, abaloparatide, which is marketed in the U.S. as TYMLOS®.

Under the terms of the agreement Pharmanovia will be responsible for clinical, regulatory and commercial activities across key markets in the Asia Pacific region, specifically China, Singapore, Thailand, Indonesia, Vietnam, Taiwan, Hong Kong, Malaysia, Macau and the Philippines.

Abaloparatide is a human parathyroid hormone related peptide analogue indicated by the FDA for the treatment of postmenopausal women with osteoporosis at high risk for fracture or patients who have failed or are intolerant to other available osteoporosis therapy. Abaloparatide is also indicated to increase bone density in men with osteoporosis at high risk for fracture or patients who have failed or are intolerant to other available osteoporosis therapy.¹

“We are thrilled to expand our portfolio and bring to the Asia Pacific region such an important and innovative osteoporosis treatment,” said James Burt, CEO, Pharmanovia. “This deal recognises the strength of our commercial model in APAC, and China in particular, where we have one of the leading osteoporosis commercial platforms.”

“With Tymlos® we will serve a broader patient population, providing osteoporosis solutions in the high, medium and low risk categories, further addressing unmet needs and meeting bone health challenges.”

“This collaboration partners two companies that share a commitment to improving the lives of patients with osteoporosis,” said Scott Briggs, CEO, Radius Health. “With Pharmanovia’s expertise in osteoporosis and their proven track record of success in these territories, we can look forward to significantly expanding access of abaloparatide to patients in need of osteoporosis treatment options.”

-Ends-

Notes to editors

For further information, please contact:

Alison Dyson, Director of Communications, Pharmanovia

07912887250/ communications@pharmanovia.com Or pharmanovia@67health.co.uk

About Pharmanovia

Pharmanovia is a global lifecycle management healthcare company. Our purpose is to make medicines fit for tomorrow, to improve the lives of patients globally.

We do this by rediscovering, repurposing or re-engineering established medicines or by bringing to market novel medicines to improve patient outcomes and experiences.

With a diverse and growing team in over 160 countries across the globe, we deliver high-quality solutions, ethically and sustainably, across our four core therapeutic areas – Endocrinology, Neurology, Cardiovascular and Oncology both in rare and established diseases or conditions.

About Radius Health

Radius is a global biopharmaceutical company dedicated to transforming the future for underserved, global patient populations in bone health and related areas. Radius’ lead product, TYMLOS® (abaloparatide) injection, was approved by the U.S. Food and Drug Administration in April 2017 for the treatment of postmenopausal women with osteoporosis at high risk for fracture, and in December 2022 to increase bone density in men with osteoporosis at high risk for fracture. Radius also has an exclusive licensing and distribution agreement for the U.S. rights to BINOSTO® (alendronate sodium) effervescent tablet for oral solution, expanding the Company’s presence in bone health.

References

¹https://radiuspharm.com/wp-content/uploads/tymlos/tymlos-prescribing-information.pdf